OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer

Puntos clave

• This study aims to evaluate the effectiveness of DHP107 (oral paclitaxel) compared to intravenous paclitaxel in treating HER2-negative recurrent or metastatic breast cancer.
• Conducted as a phase II clinical study
• Compared oral DHP107 with intravenous paclitaxel
• Targeted patients with HER2-negative breast cancer
• Analyzed efficacy and safety outcomes
• Preliminary findings indicated potential effectiveness of oral paclitaxel
• Safety profiles were comparable between the two treatment options
• Patients experienced various responses to both treatments